Forecast

There is no analyst data available for this company.

News Go to news feed

DiaSorin share falls after UBS downgrade and increased competitive pressure

DiaSorin’s stock fell 3.8% to €73.68 after UBS cut its rating from "neutral" to "sell" and reduced the price target by about 17% to €55. The bank pointed to rising competitive pressure, political headwinds from China and doubts that the new molecular diagnostics platform Liaison Nes will achieve the expected market shares. UBS sees 2026 EBIT 4–6% below consensus and criticizes a valuation premium versus peers such as bioMérieux. » More on de.investing.com
DiaSorin reports revenue decline in Q1, confirms full-year guidance

DiaSorin recorded a revenue decline in the first quarter of 2026 (constant -3%, nominal -8%) and an EPS of $0.85, which missed analysts’ estimates, weighed down by negative currency effects, pricing pressure in China and a mild flu season. Despite the setbacks, management is maintaining the full-year guidance and expects currency-adjusted revenue growth of 5–6% and an adjusted EBITDA margin of 32–33%, supported by investments in the LIAISON NES and PLEX platforms. Investors will be watching the FDA decision on the GI panel, the market launch of LIAISON NES and developments in China closely. » More on de.investing.com
DiaSorin confirms stable growth for 2025 and expects acceleration in 2026

DiaSorin reports 2025 revenue of €1,195m (+1%) and maintains an adjusted EBITDA margin of 33%. Excluding COVID-related sales, core business grew by 5%, driven by immunodiagnostics (€785m, +7% ex‑COVID) and a strong performance in North America, while China remained pressured by VBP implementation and reimbursement cuts. Molecular diagnostics showed mixed trends; automated multiplexing softened, targeted molecular diagnostics grew strongly, and new panels as well as the LIAISON PLEX/NES launches are expected to boost 2026. For 2026 management forecasts revenue growth of 5–6% at constant exchange rates and an adjusted EBITDA margin of around 32–33%, with acceleration expected in the second half of the year. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, DiaSorin has already paid 1,30€ in dividends. The last payout was in May.

Financials

In the last quarter, DiaSorin had revenue of 602.00m€ and net profit of 84.00m€

(EUR)	Jun 2026	YoY
Revenue	+602.00m	96,56%
Gross profit	+390.00m	93,15%
Net profit	+84.00m	77,20%
EBITDA	+135.00m	92,30%

Fundamentals

Metric	Value
Market capitalization	+3.73b€
Number of shares	49.45m
52-week high/low	+92,32€ - +52,34€
Dividend yield	+1,72%
Dividends TTM	+1,30€
Beta	0,69
P/E ratio	+23,51
PEG ratio	−0,87
P/B ratio	+2,97
P/S ratio	+2,14

Company profile

DiaSorin S.p.A. entwickelt, produziert und vertreibt immundiagnostische und molekulardiagnostische Testkits in Europa, Afrika, Nordamerika, Mittel- und Südamerika, im asiatisch-pazifischen Raum und in China. Das Unternehmen bietet verschiedene immundiagnostische LIAISON-Plattformen an, darunter LIAISON XS, LIAISON XL und LIAISON XL LAS, sowie eine molekulardiagnostische Plattform, bestehend aus LIAISON MDX für die Amplifikation von Nukleinsäuren zur Diagnose von Virusinfektionen durch die Identifizierung von Viren in biologischen Proben des Patienten. Das Unternehmen hat Partnerschaftsvereinbarungen mit QIAGEN für eine Diagnoselösung zum Nachweis latenter Tuberkulose, mit TTP für die Entwicklung einer molekularen Point-of-Care-Lösung und mit MeMed für die Einführung eines Tests zur Unterscheidung zwischen viralen und bakteriellen Infektionen. Das Unternehmen wurde 1968 gegründet und hat seinen Hauptsitz in Saluggia, Italien.